➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Baxter
Boehringer Ingelheim
Medtronic
Merck

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 10,456,479

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,456,479
Title:Hydrophilic linkers and ligand-drug conjugates thereof
Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.
Inventor(s): Sun; Sanxing (Hangzhou, CN), Zhao; Robert Yongxin (Hangzhou, CN), Li; Xing (Hangzhou, CN), Guo; Huihui (Hangzhou, CN), Jia; Junxiang (Hangzhou, CN), Xie; Hongsheng (Hangzhou, CN), Zhou; Xiaomai (Hangzhou, CN), Huang; Yuanyuan (Hangzhou, CN), Yang; Qingliang (Hangzhou, CN), Zhuo; Xiaotao (Hangzhou, CN), Ye; Hangbo (Hangzhou, CN), Gai; Shun (Hangzhou, CN), Qu; Lan (Hangzhou, CN), Li; Wenjun (Hangzhou, CN), Lin; Chen (Hangzhou, CN)
Assignee: HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)
Application Number:15/558,917
Patent Claims:see list of patent claims

Details for Patent 10,456,479

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2039-10-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2039-10-29 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2039-10-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Express Scripts
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.